Fetoscopic Selective Laser Photocoagulation in Twin-Twin Transfusion Syndrome

Launched by EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT (NICHD) · Jun 27, 2006

Keywords

ClinConnect Summary

We hypothesize that treatment of the underlying chorioangiopagus by selective fetoscopic laser photocoagulation will not only improve the survival of twins but will reduce the incidence of neurologic, cardiac, and developmental sequelae of twin-twin transfusion syndrome (TTTS). We propose to test this hypothesis by a prospective randomized multicenter trial to compare serial amnioreduction with selective fetoscopic laser photocoagulation in cases of severe (stage II-IV) twin-twin transfusion syndrome (TTTS). Primary Outcomes: Survival of donor twin at 30 days after birth and no treatment fa...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Both twins are alive
• • TTTS diagnosed prior to 22 weeks gestation
• • Monochorionic diamniotic gestation
• • Like sex twins
• • Single placental mass
• • Thin intertwin membrane
• • Oligohydramnios in donor twin (deepest vertical pocket of ≤ 2 cm)
• • Polyhydramnios with deepest vertical pocket of \> 8 cm with or without Doppler or echocardiographic changes in the recipient twin (deepest vertical pocket of \> 6 cm if previous amnioreduction)
• • Decompressed bladder in donor not seen to fill during the ultrasound examination (stage II, III, or IV), unless Doppler velocimetry changes (absent end-diastolic umbilical artery flow, abnormal ductus venosus waveform), and/or echocardiographic changes (valvular insufficiency, ventricular hypertrophy) are already present
• • No associated structural abnormalities
• • No sonographic evidence of CNS injury at time of entry
• • No preterm labor
• • No maternal medical contraindication to anesthesia or surgery
• Exclusion Criteria:
• • Failure to meet all inclusion criteria
• • TTTS presenting after 22 weeks gestation
• • Randomization after 24 weeks gestation
• • Cervical length \< 2.0 cm post initial
• • Presence of cervical cerclage
• • Uterine anomaly
• • Refusal to accept randomization
• • Unable to pursue prenatal care at an approved center coordinated by one of the participating institutions
• • Unable to pursue postnatal evaluation at a NICHD Neonatal Research Network Institution

Trial Officials